| Literature DB >> 29939287 |
Roberto Paredes1,2, Marion Schneider1,2, Adam Stevens2,3, Daniel J White1,2, Andrew J K Williamson1,2, Joanne Muter1,2, Stella Pearson1,2, James R Kelly1,2, Kathleen Connors1,2, Daniel H Wiseman2,4, John A Chadwick2,4, Harald Löffler5, Hsiang Ying Teng1,2, Simon Lovell2,6, Richard Unwin1,2, Henri J van de Vrugt7, Helen Smith2,6, Olga Kustikova8, Axel Schambach8, Tim C P Somervaille2,4, Andrew Pierce1,2, Anthony D Whetton1,2,9, Stefan Meyer1,2,10,11.
Abstract
The transcriptional regulator EVI1 has an essential role in early hematopoiesis and development. However, aberrantly high expression of EVI1 has potent oncogenic properties and confers poor prognosis and chemo-resistance in leukemia and solid tumors. To investigate to what extent EVI1 function might be regulated by post-translational modifications we carried out mass spectrometry- and antibody-based analyses and uncovered an ATM-mediated double phosphorylation of EVI1 at the carboxy-terminal S858/S860 SQS motif. In the presence of genotoxic stress EVI1-WT (SQS), but not site mutated EVI1-AQA was able to maintain transcriptional patterns and transformation potency, while under standard conditions carboxy-terminal mutation had no effect. Maintenance of hematopoietic progenitor cell clonogenic potential was profoundly impaired with EVI1-AQA compared with EVI1-WT, in particular in the presence of genotoxic stress. Exploring mechanistic events underlying these observations, we showed that after genotoxic stress EVI1-WT, but not EVI1-AQA increased its level of association with its functionally essential interaction partner CtBP1, implying a role for ATM in regulating EVI1 protein interactions via phosphorylation. This aspect of EVI1 regulation is therapeutically relevant, as chemotherapy-induced genotoxicity might detrimentally sustain EVI1 function via stress response mediated phosphorylation, and ATM-inhibition might be of specific targeted benefit in EVI1-overexpressing malignancies.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29939287 PMCID: PMC6125627 DOI: 10.1093/nar/gky536
Source DB: PubMed Journal: Nucleic Acids Res ISSN: 0305-1048 Impact factor: 16.971
Figure 1.Carboxy-terminal EVI1 phosphorylation. Mass spectrometry analysis of the EVI1 peptide Asn849-Arg862 from SB1690CB AML cells, demonstrating the presence of non-phosphorylated (A) and single Ser860 phosphorylated peptides (B) in untreated SB1690CB cells. y- and b-type ions illustrating their position within the peptide sequence indicated. The mass/charge ratio (m/z) of the precursor ion is also shown. (C) Schematic representation of the EVI1 protein with sequence alignment of EVI1 from other species as indicated, showing DNA binding zinc finger domains (ZF), CtBP1 binding motifs (CtBP) and acidic domain (AC). Carboxy-terminal phosphorylation sites are shown in red circles and annotated in relation to the EVI1-SQS containing epitope alignment. (D) Confirmation of induction of DNA damage by γH2AX foci formation after H2O2 or radiation treatment of SB1690CB cells (left panel). White arrowheads denote cells with increased number of foci (green signal). DAPI co-stain for the nucleus (blue signal). Western blot (right panel) of γH2AX and p-p53 (Ser15) as markers of DNA damage response activation and ATM activity after H2O2-treatment of SB1690CB cells. (E) EVI1 MS spectrum obtained for peptide Asn849-Arg862 from irradiated SB1690CB cells, inferring double phosphorylation of the carboxy-terminal S858/S860 SQS motif.
Figure 2.Induction of EVI1 double phosphorylation by DNA damage. (A) Immunoprecipitated EVI1 from SB1690CB cells probed with anti-pS860-EVI1 (upper panel), and anti-pS858/pS860-EVI1 antibody, untreated (lane 1), and after 1 and 2 h (lane 2 and 3) post radiation. (B) Western blot (WB) of EVI1-immunoprecipitates from untreated (lanes 1 and 2) and irradiated (lanes 3 and 4) SB1690CB cells pre-treated (1 h) with 10 μM ATM-kinase inhibitor KU55933 (lanes 2 and 4), and not pre-treated (lanes 1 and 3). Membranes were probed for doubly phosphorylated EVI1 with anti-pS858/pS860-EVI1 antibody. Middle panel: membrane as upper panel re-probed with pan-EVI1 antibody. Lower panel: WB of p-p53 (Ser15) carried out on input samples as positive control for ATM-activity and ATM-inhibition.
Figure 3.Effect of EVI1-WT and EVI1-AQA on transcription. (A) Luciferase assays on promoters of EVI1-repressed PLZF (left panel) and FOS (right panel) transcripts (n = 4, t-test, ns: not significant). (B) Heat map illustration of significantly differentially expressed transcripts (P < 0.01) after transfection with EVI1-WT and EVI1-AQA of untreated cells (left half of the heatmap), and after treatment with H2O2 (150 μM, right half of the heat map, indicated by black line) (n = 1306). The heatmap was generated applying a group ANOVA analysis to the entire dataset. Clusters of EVI1 regulated transcripts were identified by dendrogram delineation, and boxed for repressed (1A and 1B), and upregulated transcripts (2A and 2B). Patterns of sub-clusters in H2O2 treated cells with different changes comparing EVI-WT with EVI1-AQA indicated by arrow in 1B and dashed box in 2B.
Figure 4.EVI1-mediated Rat-1 fibroblast transformation. (A) Rat-1 fibroblast colonies of untransduced, stably MSCV-, EVI1-WT- or EVI1-AQA-transduced fibroblasts. Rat-1 fibroblasts were left untreated, H2O2-treated (B) or irradiated with 0.5 and 2Gy as indicated (C) (n = 4). Statistical analysis: t-test (*P < 0.05, ns: not significant).
Figure 5.EVI1-mediated serial replating of murine hematopoietic progenitor cells. (A) Schematic representation of hematopoietic progenitor clonogenic replating: cKit+ cells were transduced, selected for transduction, and plated in the presence or absence of H2O2 (first round). Colonies were counted after 7 days, harvested and replated (second round). H2O2 treated cells were split in two batches (red arrows) to be left untreated or treated with a second dose of H2O2. Untreated cells were re-plated untreated (green arrow). Remaining cells were used for a third round of replating. (B) Colony count after first round (n = 8, from eight different mice, black: H2O2 treated). (C and D) Colony counts after the second and third rounds of replating (n = 8, from eight different mice). White: untreated; gray: untreated cells replated from previously H2O2 treated colonies; black: H2O2 treatment in all rounds. Inserts C and D: direct comparison between untreated EVI1-WT and EVI1-AQA transduction with and without damage. Statistical analysis: paired t-test (*P < 0.05, **P < 0.01). (E) May-Grünwald Giemsa stained cells from colonies after first culture. Red arrowheads point typical blast-like cell morphology. (F) Blast-like cells quantitation from the first round of replating. Statistical analysis: one-way ANOVA (**P < 0.01, ***P < 0.001).
Figure 6.Nuclear association of EVI1 with CtBP1. (A) EVI1 (green) and CtBP1 (red) immunofluorescence signal of HEK293T cells transfected with EVI1-WT (upper panel) and EVI1-AQA mutant (middle panel), or SB1690CB AML cells (lower panel) after genotoxic stress induced either with H2O2 treatment or irradiation (2 Gy). Left top corner inserts represent 4 μm2 regions of interests (ROI) in HEK293T cells or 3 μm2 ROIs in SB1690CB cells (eight ROIs/cell analyzed). (B) Quantification of EVI1 and CtBP1 co-localization in EVI1-WT or EVI1-AQA transfected HEK293T cells after genotoxic stress. Degree of co-localization is expressed as Pearson's Coefficient (P’sC). Each bar represents the average P’sC of independent experiments (n = 3) for H2O2 (left panel) and irradiated cells (right panel). (C) Distribution of P’sC for endogenously expressed EVI1 and CtBP1 co-localization in SB1690CB leukemia cells after H2O2 treatment or irradiation. Each dot represents a single cell (left panel). Average P’sC of independent experiments (n = 3) plotted as bar graphs (right panel). Statistical analysis: one-way ANOVA (*P < 0.05, **P < 0.01, ***P < 0.001, ns = not significant).
Figure 7.Effect of genotoxic stress on EVI1-CtBP1 interaction. (A) Western blot analysis of flag-antibody immunoprecipitated tagged EVI1 and co-immunoprecipitated CtBP1 from total cell protein extracts of untreated Flag-tagged EVI1-WT or EVI1-AQA transfected HEK293 cells (upper panel: EVI1; lower panel: CtBP1). (B) Signal quantification of serial biological replicates (n = 3) at 3 min (n.s. = not significant, t-test). (C) Western blot analysis of flag-antibody immunoprecipitated EVI1 and co-immunoprecipitated CtBP1 from total cell protein extracts of H2O2 treated Flag-tagged EVI1-WT and EVI1-AQA transfected cells (upper panel: EVI1; lower panel CtBP1). (D) Signal quantification of biological replicates (n = 3) (*P < 0.05, t-test).